The 5th Inner Ear Disorders Therapeutics Summit arrives at a pivotal moment in the field, as breakthroughs in gene therapy, small molecules, and cell-based therapies reignite hope for treating hearing loss.

Following significant clinical successes from Regeneron & Eli Lilly, 2025 offers renewed optimism and momentum in genetic hearing loss treatments. However, challenges remain across preclinical, translational, and clinical stages, underscoring the need for collaboration. This event brings together leaders from biotech, pharma, VC’s and academia to address these hurdles, discuss cutting-edge research, and explore opportunities in drug-device combinations, creating a unique platform for advancing hearing loss therapeutics in 2025.

Event link here.